Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

Trial Details

NCT ID
NCT04741997
Phase
EARLY_PHASE1
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
BRAF Mutated Melanoma
Interventions
  • Encorafenib Pill
  • Binimetinib Pill
  • Nivolumab
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Age ≥ 18 years at the time of informed consent
  • Histologically confirmed diagnosis of melanoma. Any primary or unknown origin is permitted.
  • Melanoma must have a BRAFV600 mutation (using a CLIA-validated assay), either stage III (B/C/D) or Stage IV (AJCC 8th edition).
  • ECOG performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find BRAF Mutated Melanoma Trials on Trialify →